"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1997 | 0 | 1 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 4 | 5 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 6 | 1 | 7 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial. J Stroke Cerebrovasc Dis. 2024 Sep; 33(9):107839.
-
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. Am Heart J. 2023 06; 260:124-140.
-
Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study. ASAIO J. 2023 06 01; 69(6):595-601.
-
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022 03; 53(3):728-738.
-
Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study. Clin Gastroenterol Hepatol. 2022 02; 20(2):381-389.e9.
-
Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III. Neurocrit Care. 2020 10; 33(2):516-524.
-
The Point-of-Care INR Test for Vitamin K Antagonist Monitoring. JAMA. 2019 12 03; 322(21):2129-2130.
-
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
-
Management of Patients With Atrial Fibrillation. JAMA. 2019 Mar 19; 321(11):1100-1101.
-
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30.